- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07188558
- Ursprunglig rättegång
En studie för att undersöka Ronde-Cel kontra Investigator's Choice CD19 CAR T-cellterapi (PiNACLE-H2H)
En fas 3 randomiserad kontrollerad studie av RondecabTagene Autoleucel, en autolog, dubbelinriktande CD19/CD20 CAR T-cellproduktkandidat, kontra utredarens val av CD19 CAR T-cellterapi hos patienter med återfall eller eldfast stor B-celllymfom i andra linjeinställningen
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Mary Lessig, MS
- Telefonnummer: 000-000-0000
- E-post: clinicaltrials@lyell.com
Studera Kontakt Backup
- Namn: James Dean, MD, PhD
- Telefonnummer: 000-000-0000
- E-post: clinicaltrials@lyell.com
Studieorter
-
-
Queensland
-
Douglas, Queensland, Australien, 4814
- Rekrytering
- Townsville University Hospital
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekrytering
- The Alfred
-
-
-
-
Arizona
-
Gilbert, Arizona, Förenta staterna, 85234
- Rekrytering
- Banner MD Anderson Cancer Center
-
Scottsdale, Arizona, Förenta staterna, 85258
- Rekrytering
- Honor Health
-
Scottsdale, Arizona, Förenta staterna, 85259
- Rekrytering
- Mayo Clinic Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- Har inte rekryterat ännu
- University of Arkansas
-
-
California
-
Los Angeles, California, Förenta staterna, 90048
- Rekrytering
- Cedars-Sinai Medical Center
-
Los Angeles, California, Förenta staterna, 90095
- Rekrytering
- University of California, Los Angeles (UCLA)
-
Orange, California, Förenta staterna, 92868
- Rekrytering
- University of California, Irvine
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Rekrytering
- University of Colorado
-
Denver, Colorado, Förenta staterna, 80218
- Rekrytering
- Colorado Blood Cancer Institute
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20007
- Rekrytering
- MedStar Georgetown University Hospital
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32224
- Rekrytering
- Mayo Clinic Florida
-
Orlando, Florida, Förenta staterna, 32804
- Rekrytering
- AdventHealth
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30342
- Rekrytering
- Northside Hospital
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- Rekrytering
- University of Chicago
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Northwestern
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- Rekrytering
- University of Iowa
-
-
Kansas
-
Westwood, Kansas, Förenta staterna, 66205
- Rekrytering
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40202
- Rekrytering
- University of Louisville Health
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02111
- Rekrytering
- Tufts Medical Center
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Rekrytering
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68105
- Rekrytering
- University of Nebraska Medical Center (UNMC)
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Rekrytering
- Hackensack
-
Morristown, New Jersey, Förenta staterna, 07960
- Rekrytering
- Atlantic Health
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87102
- Rekrytering
- University of New Mexico Comprehensive Cancer Center
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263
- Rekrytering
- Roswell Park Comprehensive Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Rekrytering
- Duke Cancer Institute
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Har inte rekryterat ännu
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45267
- Rekrytering
- University of Cincinnati
-
Cincinnati, Ohio, Förenta staterna, 45242
- Rekrytering
- Oncology Hematology Care Clinical Trials
-
Cleveland, Ohio, Förenta staterna, 44195
- Rekrytering
- Cleveland Clinical Taussig Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- Har inte rekryterat ännu
- Allegheny Health Network
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Förenta staterna, 78704
- Rekrytering
- St. David's South Austin Medical Center
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- University of Texas Southwestern Medical Center
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- MD Anderson Cancer Center
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- Texas Transplant Institute
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84143
- Rekrytering
- Intermountain Healthcare
-
-
Virginia
-
Norfolk, Virginia, Förenta staterna, 23502
- Rekrytering
- Virginia Oncology Associates
-
Richmond, Virginia, Förenta staterna, 23298
- Rekrytering
- Virginia Commonwealth University-Massey Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Rekrytering
- Medical College of Wisconsin
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2C4
- Rekrytering
- Princess Margaret Cancer Centre
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
-
CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
-
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
-
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
-
Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Key Exclusion Criteria:
- Patients ineligible to receive CD19 CAR T-cell therapy
- Primary CNS lymphoma
- Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
- Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
- Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Rondecabtagene autoleucel
|
An autologous, dual-targeting CD19/20 CAR T-cell candidate.
Andra namn:
|
|
Aktiv komparator: Investigator's Choice CD19
axicabtagene ciloleucel, lisocabtagene maraleucel |
An autologous CD19 CAR T-cell therapy
Andra namn:
An autologous CD19 CAR T-cell therapy
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Event free survival
Tidsram: 36 months
|
The time interval from treatment initiation until the occurrence of a specific event of interest. |
36 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Response Rate
Tidsram: 36 months
|
Best Overall Response per Lugano Criteria |
36 months
|
|
Complete Response Rate
Tidsram: 36 months
|
Complete Response per Lugano Criteria |
36 months
|
|
Progression Free Survial
Tidsram: 36 months
|
The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. |
36 months
|
|
Overall Survival
Tidsram: 6 years
|
The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive. |
6 years
|
|
Incidence and severity adverse events
Tidsram: 36 months
|
To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities. |
36 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- LYL314-102
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .